Aurora Cannabis Denies Acquisition of MedLeaf Therapeutics

LOS ANGELES- Aurora Cannabis Inc. publicly refuted recent reports claiming it was acquiring New Zealand–based MedLeaf Therapeutics. In a statement issued on June 18, 2025, the Edmonton-headquartered company confirmed it “has not entered into any such agreement, has had no discussions with MedLeaf Therapeutics with respect to any business combination transaction, and has not made any statement or filed any information pertaining to any such transaction”.

The update followed publication of an article on Investing.com and similar reports that suggested Aurora had signed a $215 million cash-and-stock deal for MedLeaf Therapeutics—claims the company labelled “entirely false” and “misinformation”. Aurora also dismissed a separate, simultaneously issued claim of a strategic partnership with Germany’s MediPharm GmbH, emphasising that no discussions or agreements have occurred.

Aurora attributed the false narrative to AI‑generated content reviewed by Investing.com, casting scrutiny on the editorial accuracy of such reporting. To reinforce transparency, the company encouraged investors and stakeholders to rely only on official communications—such as regulatory filings and corporate press releases—for material updates.

The episode spotlights growing risks posed by unverified digital content in financial journalism. As AI becomes more widely used in news production, public companies may face increased pressure to monitor and correct inaccurate disclosures promptly. Aurora’s swift and decisive response underscores the importance of fact-checked, reliable sourcing in the cannabis sector.